Iron overload in Myelodysplastic Syndromes: Evidence Based Guidelines from the Canadian Consortium on MDS

The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders that lead to bone marrow failure and an increased risk of progression to acute myelogenous leukemia (AML). As many as one in 1000 Canadians over the age of 65 years may be affected [1], and data from the Surveillance, Epidemiology, and End Results (SEER) Program in the United States (US) indicates an MDS incidence up to 4.5 per 100,000 per year, or 10,000 or more new MDS diagnoses yearly [2]. The incidence of MDS increases with age, with 0.5, 5.3, 15, 49, and 89 cases per 100,000 in the age groups

Source: Leukemia Research - September 19, 2018 Category: Hematology Authors: Heather A. Leitch, Rena Buckstein, Nancy Zhu, Thomas J. Nevill, Karen W.L. Yee, Brian Leber, Mary-Margaret Keating, Eve St. Hilaire, Rajat Kumar, Robert Delage, Michelle Geddes, John M. Storring, April Shamy, Mohamed Elemary, Richard A. Wells Source Type: research